This observational, case-only study (n=25) will investigate the self-administered therapeutic use of psychedelics in people with psychiatric disorders.
Led by University Hospital, Toulouse, the study aims to understand the current use of psychedelics in France among individuals who have used these substances to suppress or alleviate psychiatric symptoms within diagnosed pathologies. The study will involve semi-structured interviews to collect data, which will then undergo thematic analysis.
Participants eligible for the study include adults diagnosed with a psychiatric disorder who have used psychedelic or related substances for therapeutic purposes. Exclusion criteria include individuals who do not speak or understand French and those under protection, guardianship, or curatorship.
The estimated start date for the study was November 30, 2023, with an estimated completion date of March 10, 2025, and an anticipated enrolment of 25 participants.
Trial Details
This study is set up to better understand the current use of psychedelics in France in the general population. The present focus on individuals who have used any type of psychedelic drug in order to suppress or alleviate a psychiatric symptom in the context of a diagnosed pathology. The data are collected during a semi-structured interview and then studied in a thematic analysis.NCT Number NCT06014164
Sponsors & Collaborators
University Hospital ToulouseThe University Hospital of Toulouse (CHU de Toulouse) is a leading medical institution located in Toulouse, France. It provides comprehensive healthcare services, conducts medical research, and offers educational programs for healthcare professionals